Table 1 Patient demographics and date of engineered T cell infusion.

UPN, unique patient number; MM, multiple myeloma; BM, bone marrow; XRT, radiation therapy; ASCT, autologous hematopoietic stem cell transplant; ND, not done.

Subject ID (UPN) /
Infusion date
Gender / AgeDiagnosisClinical SitesPrior TherapyPrior Transplant / SurgeryLAGE-1* /NY-ESO-1* /NY-ESO-1**
UPN35
1/7/19
Female /
66 years
IgG kappa MM 2008BM, lytic bone lesionsLenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, panobinostat
(8 lines; see supplementary materials)
ASCT x 3Pos/Pos/Neg
UPN39
3/18/19
Male /
66 years
Myxoid/round cell liposarcoma 2012Abdominal/
pelvic masses
Doxorubicin, ifosfamide, XRT 60-Gy, trabectedin, gemcitabine, taxol, XRTResection/
debulking × 2, left nephrectomy/ partial sigmoid resection
ND/ND/Pos
UPN07
8/5/19
Female /
62 years
Kappa light chain MM 2009BM, lytic bone lesionsLenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, anti-CD38 immunoconjugate (6 lines; see supplementary materials)ASCT x 2Pos/Pos/Neg

*qPCR

**Immunohistochemistry